Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Arch. esp. urol. (Ed. impr.) ; 76(2): 139-144, 28 mar. 2023. graf, tab
Artigo em Inglês | IBECS | ID: ibc-219640

RESUMO

Objective: To describe the profile of patients with erectile dysfunction (ED), attending to consultation and satisfaction using sildenafil oral suspension, from the specialist’s perception. Materials and methods: This is a nationwide multicenter, epidemiological, descriptive and observational study, with the studied population as the unit of study. Thirty urologists and/or andrologists completed a questionnaire with questions about ED patients’ profile attending to their practice, sildenafil oral suspension perception of effectiveness and safeness, and their opinion about patients’ satisfaction after sildenafil oral suspension treatment. Aggregate data were collected for the last 6 patients treated or on treatment with sildenafil oral suspension. Results: Overall, 40.9% and 24.9% of patients had moderate or severe ED, respectively. Among the patients, 73.6% were older than 50 years. The disease progression was approximately one year (11.8 months). ED etiology was mostly organic (38.1%) and mixed (31.8%). Cardiovascular comorbidities were present in 57.4%, mental health problems in 16.4% and hormonal disorders in 10.2% of the patients. The main reason for choosing sildenafil oral suspension was the ease of dose adjustment. The specialists considered that 73.4% of the patients responded satisfactorily to treatment. They also rated the perceived effectiveness and safeness of the product as very good or good. Conclusions: Urologists and andrologists consider that most patients with ED achieve a high degree of satisfaction with sildenafil oral suspension. The main advantage of the treatment is the possibility of adjusting the dose according to patient’s needs and circumstances (AU)


Assuntos
Humanos , Masculino , Pesquisas sobre Atenção à Saúde , Disfunção Erétil/tratamento farmacológico , Citrato de Sildenafila/administração & dosagem , Agentes Urológicos/administração & dosagem , Padrões de Prática Médica , Espanha
4.
Rev. int. androl. (Internet) ; 18(2): 75-78, abr.-jun. 2020.
Artigo em Espanhol | IBECS | ID: ibc-193763

RESUMO

OBJETIVOS: La utilización con fines recreativos de sustancias de abuso asociadas a algunos medicamentos también empleados en estos contextos obliga al profesional a conocer la posibilidad de interacciones entre ambos. El objetivo de la presente revisión sistemática es actualizar la información disponible sobre la seguridad cardiovascular de la asociación de cannabis y sildenafilo. MATERIALES Y MÉTODOS: Se llevó a cabo una revisión sistemática en las bases de datos PubMed, PreMedline, Medline, Embase, ChemID, HSRPROJ, POPLINE y TOXLINE, desde el inicio de las bases de datos hasta el 1 de marzo del 2018 con los términos clave «sildenafil», «vardenafil», «tadalafil», «phosphodiesterase inhibitors» y «cannabis», combinándolos y cruzándolos mediante operadores booleanos con «adverse effects» y «cardiovascular». No se restringió por idioma ni por tipo de estudio. RESULTADOS: Se encontraron 13 publicaciones, de las cuales 5 analizaban la combinación de cannabis y sildenafilo como un nuevo estilo de uso recreativo, no médico, del consumo conjunto de ambas sustancias, pero solo 3lo relacionaban con alteraciones cardiacas: un infarto posterior sin onda Q, otro sin elevación ST y un síndrome coronario agudo. CONCLUSIONES: La gravedad de los eventos cardiovasculares de sildenafilo asociado a cannabis obliga al profesional a tenerlos en cuenta ante cuadros de miocardiopatía isquémica de difícil filiación


OBJECTIVES: The recreational use of drugs of abuse associated to therapeutically used drugs in sexual contexts forces the health care professional to know the possibility of drug-drug interactions among them. The aim of this review is updating the available information on cardiovascular safety of recreational use of sildenafil and cannabis. MATERIALS AND METHODS: A systematic search in databases PubMed, PreMedline, Medline, Embase, ChemID, HSRPROJ, POPLINE and TOXLINE, from the start of the databases until to March 1, 2018 was made. Search terms were "sildenafil", "vardenafil", "tadalafil", "phosphodiesterase inhibitors" and "cannabis", combining and crossing them by means of Boolean operators with "adverse effects" and "cardiovascular". No restrictions for language or type of study were made. RESULTS: Thirteen papers were found, 5out of them analyzed cannabis and sildenafil combination as a new style of recreational non-medical use. Only 3papers related sildenafil-cannabis association with cardiovascular events: one posterior myocardial infarction without Q wave, one myocardial infarction without ST elevation and one acute coronary syndrome. CONCLUSIONS: Severity of sildenafil-cannabis-related cardiovascular events forces the healthcare professionals to take them into account and considering them in clinical pictures of an ischemic cardiomyopathy hard to classify


Assuntos
Humanos , Masculino , Uso da Maconha/efeitos adversos , Citrato de Sildenafila/efeitos adversos , Interações Medicamentosas , Vasodilatadores/efeitos adversos , Drogas Ilícitas/efeitos adversos , Doença das Coronárias
5.
Eur. j. anat ; 23(2): 113-119, mar. 2019. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-182421

RESUMO

Nephrotoxicity is considered the most important side effect which limits cisplatin therapy in various diseases. It is might be due to oxidative stress, decreased renal blood flow and reduction in the glomerular filtration. Sildenafil citrate is used for treatment of erectile dysfunction, but its effect in ameliorating cisplatin nephrotoxicity was not yet clearly studied. So the present work aimed to evaluate the protective role of Sildenafil citrate against cisplatin-induced nephrotoxicity in adult male albino rats. 24 adult male albino rats were divided into 4 groups (6 rats each): Group I, control; Group II, sham control; Group III, Cisplatin-treated group, and Group IV, Sildenafil-and-Cisplatin-treated group. At the end of the experiment, the kidney of each animal was excised, trimmed and prepared for histological, histochemical and immunohistochemical study. Blood samples were obtained to evaluate the kidney functions. Kidney sections of Group III showed marked degenerative changes in the proximal convoluted tubules, vacuolations, exfoliation of the lining epithelium, cast formation and interstitial hemorrhagic exudate. There was marked elevation of serum creatinine and urea with significant increase in nitric oxide (NO) and decrease in glutathione reductase (GSH) concentrations in the kidney tissue and weak periodic acid Schiff (PAS) reaction. Treatment with Sildenafil citrate in Group IV offered marked improvement in the renal structure, kidney function tests and other parameters. The present study concluded that Sildenafil citrate could protect the kidney against Cisplatin-induced nephrotoxicity in adult male albino rat


No disponible


Assuntos
Animais , Ratos , Estresse Oxidativo/efeitos dos fármacos , Citrato de Sildenafila/efeitos adversos , Antineoplásicos/efeitos adversos , Nefropatias/induzido quimicamente , Cisplatino/efeitos adversos , Ratos Sprague-Dawley , Animais de Laboratório/anatomia & histologia
8.
Rev. int. androl. (Internet) ; 16(1): 15-19, ene.-mar. 2018. ilus
Artigo em Espanhol | IBECS | ID: ibc-170575

RESUMO

Objetivo. Evaluar la utilidad del tadalafilo en el tratamiento de la disfunción eréctil a consecuencia de una lesión uretral posterior. Material y métodos. Estudio retrospectivo que incluyó pacientes con lesión uretral posterior a consecuencia de fractura de pelvis, tratados en primera instancia mediante realineamiento uretral de urgencia y posteriormente uretroplastia término-terminal entre las 8-10 semanas posteriores al trauma. Para evaluar el grado de disfunción eréctil previa y postratamiento con tadalafilo se aplicó el cuestionario Índice Internacional de Función Eréctil (IIEF-5). Se realizó la prueba estadística de rangos de Willcoxon y estadística descriptiva. Resultados. Se incluyeron 8 pacientes en este estudio, los cuales tuvieron una media de edad de los 32,5 años. La escala IIEF previa al tratamiento con tadalafilo estuvo en promedio de 8,5puntos y tuvo un aumento postratamiento de 12,36 puntos, con una valor de p=0,011. Discusión Los 8 pacientes incluidos mostraron disfunción eréctil al momento de la evaluación IIEF, esto debido al realineamiento uretral de urgencia y derivada del trauma ocasionado por la fractura de pelvis. El tratamiento con inhibidores de la 5-fosfodiesterasa (iPDE5) es el de primera línea en pacientes con disfunción eréctil debido a que es eficiente, no invasivo y bien tolerado. En este estudio encontramos resultados que indican buena respuesta a este tratamiento en 7 de los 8 pacientes (87,5%). Solo un paciente no mostró mejoría con el tratamiento, sobresaliendo la presencia de factores de riesgo, como la edad (65 años), el tabaquismo y la hipertensión arterial. Conclusión. Se rehabilitó el 87,5% de los pacientes con lesión uretral medicados con tadalafilo (AU)


Objective. To evaluate the tadalafil effect in the treatment of erectile dysfunction as a consequence of posterior urethral injury. Material and methods. This is a retrospective study that included patients with posterior urethral injury caused by previous pelvic fracture; our patients received emergency urethral alignment and urethroplasty between 8 to 10 weeks after trauma. To assess the degree of erectile dysfunction pre- and post-treatment, we applied the questionnaire of International Index of Erectile Function (IIEF-5). Statistics Wilcoxon test and descriptive statistics were performed. Results. Eight patients were included in this study, with an average age of 32.5 years; the IIEF scale prior to treatment was on average 8.5 points and increased to 12.36 points with a value of P=.011. Discussion. These eight patients showed erectile dysfunction at the time of IIEF assessment, this due to emergency urethral realignment arising from the trauma caused by pelvic fracture. Treatment with inhibitors of 5-phosphodiesterase (iPDE5) is the first-line treatment in patients with erectile dysfunction because it is efficient, non-invasive and well tolerated. In this study we found results indicating good response to this treatment in 7 out of the 8 patients (87.5%). Only one patient showed no improvement after treatment, due to the presence of risk factors such as age (65 years), tobacco use, and high blood pressure. Conclusion. The 87.5% of patients with urethral injury medicated with tadalafil were rehabilitated (AU)


Assuntos
Humanos , Tadalafila/farmacocinética , Fraturas Ósseas/complicações , Disfunção Erétil/tratamento farmacológico , Uretra/lesões , Pelve/lesões , Resultado do Tratamento , Incontinência Urinária/epidemiologia , Estudos Retrospectivos , Citrato de Sildenafila/farmacocinética
9.
Rev. int. androl. (Internet) ; 16(1): 28-33, ene.-mar. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-170577

RESUMO

Actualmente existe un debate acerca del uso continuado de los inhibidores de la fosfodiesterasa 5 en el tratamiento de la disfunción eréctil. Varios estudios apoyan el beneficio que, incluso a bajas dosis, esta estrategia terapéutica tiene sobre la función eréctil -incluso en pacientes considerados difíciles de tratar-, y sobre la espontaneidad y naturalidad de las relaciones sexuales. También ha demostrado además ser bien tolerados y seguros. Más allá de la inhibición de la fosfodiesterasa 5, el efecto sobre la función eréctil parece basarse en la mejora de la función endotelial y de la oxigenación del área vascular peneana resultado del incremento del número de erecciones, restando así importancia a la farmacocinética. Aunque la evidencia es limitada, este nuevo escenario abre nuevas oportunidades en el tratamiento de pacientes para los que el tratamiento a demanda no es efectivo o apropiado, y podría favorecer la espontaneidad de la vida sexual (AU)


At present, there is debate regarding the continuous use of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Cumulative evidence supports the benefit, even at low doses, thatcontinuous treatment has on erectile function -even in difficult-to-treat patients-, and on the spontaneity and naturalness of sexual relationships. Safety and tolerability have also proven to be good. Beyond phosphodiesterase 5 inhibition, the effect of continuous treatment of erectile function appears to be based on improvement of endothelial function and oxygenation of the penile vascular bed as a result of the increased number of erections, hence playing down the importance of pharmacokinetics. Although evidence is still limited, this new scenario opens new paths for the treatment of erectile dysfunction patients in whom on-demand treatments are not effective or deemed appropriate, and would benefit the spontaneity of sexual life (AU)


Assuntos
Humanos , Masculino , Disfunção Erétil/tratamento farmacológico , Inibidores da Fosfodiesterase 5/administração & dosagem , Ereção Peniana , Tempo/análise , Tadalafila/farmacocinética , Tolerância a Medicamentos , Dicloridrato de Vardenafila/farmacocinética , Citrato de Sildenafila/farmacocinética
12.
Rev. esp. cardiol. Supl. (Ed. impresa) ; 5(supl.A): 90a-103a, 2005. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-165400

RESUMO

Recientemente se han producido importantes avances en el conocimiento de la biopatología de la hipertensión arterial pulmonar (HAP) que han cambiado la perspectiva de la enfermedad. La disfunción del endotelio vascular induce un predominio del tono vasoconstrictor, de la hipercoagulabilidad y, fundamentalmente, incrementa la proliferación celular, produciendo un remodelado vascular con obliteración progresiva de la luz y un incremento de las resistencias vasculares pulmonares. Los nuevos tratamientos médicos actuarán sobre el remodelado vascular y la disfunción endotelial. Asimismo, el número creciente de enfermedades asociadas a la HAP y la aparición de nuevas técnicas diagnósticas obligan a sistematizar el procedimiento diagnóstico y definir una clasificación. En esta revisión, se actualizan las principales novedades en la patobiología pulmonar, las modificaciones en la clasificación clínica, los cambios en las definiciones diagnósticas, las nuevas estrategias terapéuticas y las perspectivas futuras. Además, se exponen las recomendaciones de las principales sociedades científicas para el manejo del paciente con HAP (AU)


Recent advances in the understanding of biopathology in pulmonary arterial hypertension have changed the perspective of the disease. Endothelial dysfunction induces a vasocontrictive response, a hypercoagulability state and, more importantly, an increase of cellular proliferation with subsequent vascular remodeling. Pulmonary vascular resistance is therefore increased due to progressive vessel obliteration. New therapeutic approaches are focused on vascular remodeling inhibition and endothelial dysfunction. Pulmonary arterial hypertension is associated with an increasing number of different diseases, which makes necessary to establish a systematic diagnostic approach, and to define a classification. The main topics in this review will be the recent advances in pathobiology, the new clinical classification, the changes in diagnostic definitions and the last therapeutic approaches, pointing out the future directions. Finally, recent recommendations for diagnosis and treatment published by the main scientific societies are provided (AU)


Assuntos
Humanos , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/cirurgia , Epoprostenol/uso terapêutico , Citrato de Sildenafila/uso terapêutico , Artéria Pulmonar/patologia , Artéria Pulmonar , Hipertensão Pulmonar/cirurgia , Transplante de Pulmão , Hipertensão Pulmonar/classificação , Endotélio Vascular/patologia , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...